Publications by authors named "Gustavo Tapia"

Article Synopsis
  • Aggressive large B-cell lymphomas (LBCL) have diverse biological traits; detecting MYC rearrangements (MYCr) is crucial for understanding their prognosis.
  • Current recommendations urge performing cytogenetic tests on all aggressive LBCL cases to identify MYCr, but due to its low occurrence, affordable screening options are necessary.
  • Researchers developed a scoring system and algorithm based on immunohistochemical profiles of CD10, LMO2, and MYC to effectively screen for MYCr, achieving high sensitivity and predictive values in both training and validation series.
View Article and Find Full Text PDF
Article Synopsis
  • * A study involving 61 TLBCL patients analyzed their genetic characteristics compared to nodal DLBCL and primary CNS large B-cell lymphomas; findings indicated that TLBCL has fewer copy number changes but more somatic mutations than nodal DLBCL.
  • * The results highlight a unique genetic profile for TLBCL, with most cases classified as MCD, indicating genetic diversity, suggesting that this lymphoma type warrants targeted treatment strategies due to its distinct biology.
View Article and Find Full Text PDF
Article Synopsis
  • The t(14;19)(q32;q13) chromosomal rearrangement leads to the overexpression of the BCL3 gene through its juxtaposition with the immunoglobulin heavy chain (IGH) gene, affecting various lymphoid neoplasms.
  • An analysis of 13 lymphoid neoplasms with BCL3 rearrangement identified two distinct breakpoint clusters that result in different clinical outcomes: 5' breakpoints near an IGH enhancer causing overexpression of BCL3, and 3' breakpoints leading to no overexpression.
  • The study revealed that upstream BCL3-R tumors are related to atypical chronic lymphocytic leukemia while downstream BCL3-R tumors are linked to marginal zone lymphomas,
View Article and Find Full Text PDF

Despite the widespread use of combined antiretroviral therapy (cART) and the subsequent decrease in AIDS-defining cancers, HIV-related lymphomas remain a leading cause of morbidity and mortality in people with HIV (PWH). Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL) subtype in PWH. This lymphoma is a heterogeneous disease including morphological variants and molecular subtypes according to the cell of origin or the mutation profile.

View Article and Find Full Text PDF

Neoadjuvant treatment (NAT) is one of the most widely used options for HER2+ and triple negative (TN) early breast cancer (BC). Since around half of the patients treated with NAT do not achieve a pathologically complete response (pCR), biomarkers to predict resistance are urgently needed. The correlation of clinicopathological factors with pCR was studied in 150 patients (HER2 = 81; TN = 69) and pre- and post-NAT differences in tumour biomarkers were compared.

View Article and Find Full Text PDF

Aggressive large B-cell lymphomas (aLBCL) include a heterogeneous group of lymphomas with diverse biological features. One of the approaches to the diagnosis of aLBCL is based on the identification of MYC rearrangements (MYC-R), in addition to BCL2 and BCL6 rearrangements by genetic techniques, mainly fluorescent in situ hybridization (FISH). Because of the low incidence of MYC-R, the identification of useful immunohistochemistry markers to select cases for MYC FISH testing may be useful in daily practice.

View Article and Find Full Text PDF

Key Clinical Message: HHV8- and EBV-negative primary effusion lymphoma is an extremely rare neoplasm involving body cavities without detectable tumor mass. It usually presents in elderly patients without known immunodeficiency. Compared to primary effusion lymphoma, it has a better prognosis.

View Article and Find Full Text PDF

Background: Reprogramming of immunosuppressive tumor-associated macrophages (TAMs) presents an attractive therapeutic strategy in cancer. The aim of this study was to explore the role of macrophage CD5L protein in TAM activity and assess its potential as a therapeutic target.

Methods: Monoclonal antibodies (mAbs) against recombinant CD5L were raised by subcutaneous immunization of BALB/c mice.

View Article and Find Full Text PDF
Article Synopsis
  • High-quality data on bone marrow involvement (BMI) in follicular lymphoma (FL) is scarce, which prompted researchers to develop a new flow cytometry protocol using a 10-color tube to evaluate BMI.
  • Out of 52 patients studied, 67% showed BMI through flow cytometry, with a median involvement of 1.2% leukocytes, though some discrepancies were noted when compared to the gold standard of histopathology and IGH gene rearrangement.
  • The study found significant heterogeneity in immunophenotypes of FL, indicating variation among patients, but overall, the new protocol effectively detected most cases of BMI in FL.
View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on aggressive B-cell non-Hodgkin lymphoma (B-NHL) in HIV patients, specifically exploring its characteristics according to the 2017 WHO classification.
  • Researchers analyzed 75 cases using various techniques to evaluate genetic features like MYC, BCL2, and BCL6 status, as well as to assess their influence on prognosis.
  • Findings indicate that while certain genetic rearrangements are similar in HIV-positive patients and the general population, a lower frequency of BCL2 rearrangements and specific coexpressions (MYC and BCL2 in DLBCL, MUM1 in Burkitt-like lymphoma) are linked to worse outcomes for those with HIV.
View Article and Find Full Text PDF

The incidence of lymphomas is increased in people living with HIV (PLWH). Aggressive B-cell non-Hodgkin lymphomas (NHLs) are the most common and are considered an AIDS-defining cancer (ADC). Although Hodgkin lymphoma (HL) is not considered an ADC, its incidence is also increased in PLWH.

View Article and Find Full Text PDF
Article Synopsis
  • - Splenic marginal zone B-cell lymphoma (SMZL) is a complex condition with varying clinical outcomes, influenced by multiple gene mutations and diverse regulatory pathways, making it critical to identify different subgroups based on their genetic and environmental features.
  • - Researchers analyzed 303 spleen samples from an international study to understand these subgroups, ultimately identifying two main genetic clusters: NNK (58% of cases) and DMT (32% of cases), each with unique genetic profiles and survival outcomes.
  • - The study revealed two types of immune microenvironments within SMZL: immune-suppressive and immune-silent, highlighting their distinct clinical implications and the potential for improving classification and targeted therapies in this disease.
View Article and Find Full Text PDF

High Grade B Cell Lymphoma, NOS, and High Grade B Cell Lymphoma with Dual Hit or Triple Hit have been recently recategorized in the 2016 revision of the WHO classification of lymphoid neoplasms. In this study we have characterized the genetic, histopathological, and clinical features of a series of this type of lymphoid neoplasia (17 HGBCL NOS and 53 HGBCL DH/TH).HGBCL NOS showed better response to first line treatment than HGBCL with DH/TH but no significant differences in PFS or OS were found between the two categories.

View Article and Find Full Text PDF

Despite widespread use of combined antiretroviral therapy (cART) and increased life expectancy in people living with HIV (PLWH), HIV-related lymphomas (HRL) remain a leading cause of cancer morbidity and mortality for PLWH, even in patients optimally treated with cART. While the incidence of aggressive forms of non-Hodgkin lymphoma decreased after the advent of cART, incidence of Hodgkin lymphoma (HL) has increased among PLWH in recent decades. The coinfection of Epstein-Barr virus plays a crucial role in the pathogenesis of HL in the HIV setting.

View Article and Find Full Text PDF

Plasmablastic lymphoma (PBL) represents a rare and aggressive lymphoma subtype frequently associated with immunosuppression. Clinically, patients with PBL are characterized by poor outcome. The current understanding of the molecular pathogenesis is limited.

View Article and Find Full Text PDF

Flow cytometry is a useful ancillary tool for the diagnosis of nodal B cell lymphomas. Well-established antigens have diagnostic limitations. This study aimed to assess the expression of CD71, CD81, CD44 and CD39 by flow cytometry in B cell lymphomas.

View Article and Find Full Text PDF

MYC rearrangements (MYC-R) confer unfavorable prognosis to large B-cell lymphomas (LBCL). Because of the low incidence of such genetic alteration, surrogates to screen MYC-R may be useful in daily practice. Previous studies suggested that clone 1A9-1 of LMO2 loss may be a good predictor for the presence of MYC-R in LBCL.

View Article and Find Full Text PDF

The identification of individuals with null alleles enables studying how the loss of gene function affects infection. We previously described a non-functional variant in , which encodes the myeloid-cell receptor Siglec-1/CD169 implicated in HIV-1 cell-to-cell transmission. Here we report a significant association between the null variant and extrapulmonary dissemination of (Mtb) in two clinical cohorts comprising 6,256 individuals.

View Article and Find Full Text PDF

Aims: Plasmablastic lymphoma (PBL) is a rare aggressive B-cell lymphoma that frequently arises at extranodal sites in the setting of immunosuppression. The diagnosis of PBL is complex, owing to a frequent solid or cohesive growth pattern, and an often unusual immunophenotype. Several case reports have described cytokeratin (CK) expression in PBL, introducing a diagnostic pitfall.

View Article and Find Full Text PDF

Background: Within the hematopoietic compartment, fibromodulin (FMOD) is almost exclusively expressed in chronic lymphocytic leukemia (CLL) lymphocytes. We set out to determine whether FMOD could be of help in diagnosing borderline lymphoproliferative disorders (LPD).

Methods: We established 3 flow cytometry-defined groups (CLL [n = 65], borderline LPD [n = 28], broadly defined as those with CLLflow score between 35 and -20 or discordant CD43 and CLLflow, and non-CLL LPD [n = 40]).

View Article and Find Full Text PDF